Daily Archives: January 31, 2020

Nasdaq Names Roland Chai Global Chief Risk Officer

Chai, most recently Head of Post-Trade at Hong Kong Exchange, will oversee Nasdaq’s global risk program

NEW YORK and STOCKHOLM, Sweden, Jan. 31, 2020 (GLOBE NEWSWIRE) — Nasdaq (Nasdaq: NDAQ) today announced that Roland Chai, most recently Head of Post-Trade at Hong Kong Exchange, will join the executive leadership team as Chief Risk Officer (CRO). Chai will be responsible for developing, reviewing and maintaining Nasdaq’s global risk program. He will report to Adena Friedman, President and CEO, Nasdaq.

“Risk management is an essential part of Nasdaq’s global business and operations,” said Adena Friedman, President and CEO, Nasdaq. “Nasdaq is committed to building and maintaining an industry leading culture of risk management that is able to support our long-term objectives. Roland brings extensive experience in establishing and implementing risk frameworks across functions as well as strong management capabilities that will further strengthen and enhance our decision making and business operating processes. We look forward to welcoming Roland to the Nasdaq team.”

Chai will assume his new role on June 1, 2020, and will be based in Stockholm, Sweden.

“Within the capital markets, Nasdaq has demonstrated its commitment to globalizing its business and building an advanced technology company,” said Chai. “Nasdaq also is recognized as a leader in providing risk management solutions for its own markets, regulators and other industries. I’m thrilled to be joining the company to continue bolstering its global, enterprise-wide risk culture.”

Chai most recently served as Head of Post-Trade at Hong Kong Exchange where he oversaw clearing and risk management functions across equities and fixed income, currencies and commodities, as well as the exchange’s market surveillance. During his tenure, Chai re-established risk frameworks across Exchange, Listings, Mainland Commodities, Trading, and Clearing departments, amongst other accomplishments. He previously served as Group Risk Officer and Head of Clearing at Hong Kong Exchange. Prior to joining Hong Kong Exchange, Chai served as Head of Equities at LCH.Clearnet.

About Nasdaq
Nasdaq (Nasdaq: NDAQ) is a global technology company serving the capital markets and other industries. Our diverse offering of data, analytics, software and services enables clients to optimize and execute their business vision with confidence. To learn more about the company, technology solutions and career opportunities, visit us on LinkedIn, on Twitter @Nasdaq, or at www.nasdaq.com

NDAQG

Nasdaq

Yan-yan Tong
Mobile: +46 (0)73 449 66 83
yan-yan.tong@nasdaq.com

 

Taconic Biosciences Launches New Immuno-oncology Mouse Model

Expands and Broadens Taconic Biosciences’ Immuno-oncology Portfolio Application

RENSSELAER, N.Y., Jan. 31, 2020 (GLOBE NEWSWIRE) — Taconic Biosciences, a global leader in providing drug discovery animal model solutions, expands its premier immuno-oncology portfolio with the launch of the new B2m-NOG mouse model.

Immuno-oncology leverages the body’s immune system to fight cancer, increasing the ability to target the disease.  Animal models used in this therapeutic development include special mice, which model human immune system function.  Taconic’s immuno-oncology portfolio is built on the CIEA NOG mouse®, a severely immunodeficient mouse with diverse applications based on its improved ability to engraft human cells and tissues.  B2m-NOG is an important addition to this portfolio because it significantly extends the study window after human peripheral blood mononuclear (PBMC) cell engraftment, providing more time to assess reactions to target drugs.  The extended study window dramatically expands immuno-oncology study types that can be run using the B2m-NOG model compared with more expensive and time-consuming options, such as hematopoietic stem cell-engrafted models. Taconic also offers B2m-NOG mice pre-engrafted with human PBMCs.

“Taconic is in a unique position to impact immuno-oncology research,” commented Dr. Michael Seiler, vice president of commercial products at Taconic. “Combining the extended study windows possible with B2m-NOG with Taconic’s expert consultation from PhD-level field application scientists enables our customers to quickly integrate this new tool into their experimental workflow.”

To learn more about Taconic Biosciences’ humanized model portfolio, please contact Taconic at 1-888-TACONIC (888-822-6642) in the US, +45 70 23 04 05 in Europe, or email info@taconic.com.

About Taconic Biosciences, Inc.

Taconic Biosciences is a fully-licensed, global leader in genetically engineered rodent models and services. Founded in 1952, Taconic provides the best animal solutions so that customers can acquire, custom-generate, breed, precondition, test, and distribute valuable research models worldwide. Specialists in genetically engineered mouse and rat models, microbiome, immuno-oncology mouse models, and integrated model design and breeding services, Taconic operates three service laboratories and six breeding facilities in the U.S. and Europe, maintains distributor relationships in Asia and has global shipping capabilities to provide animal models almost anywhere in the world.

Media Contact:

Kelly Owen Grover
Director of Marketing Communications
(518) 697-3824
kelly.grover@taconic.com

Lyfebulb and Helsinn Announce the Winners of the Third Annual Lyfebulb-Helsinn Cancer Innovation Summit & Award

Lyfebulb and Helsinn Announce the Winners of the Third Annual Lyfebulb-Helsinn Cancer Innovation Summit & Award

 MONACO, PRINCIPALITY OF MONACO, AND NEW YORK, NY, USA, January 31, 2020: Lyfebulb, a patient empowerment platform that connects patients with industry to support user-driven innovation toward solutions in chronic disease, and Helsinn, a Swiss pharmaceutical group focused on building quality cancer care, announce that Russell LaMontagne of Boston Immune Technologies and Therapeutics was chosen as the winner of the Lyfebulb-Helsinn Innovation Award, and Cesare Spadoni, PhD, of Oncoheroes Biosciences was chosen as the winner of the Squinto-LePera Award by Lyfebulb. In addition, the jury decided to award Michael Stein, PhD, of Valo Therapeutics a third grant. The Awards recognize outstanding Patient Entrepreneurs building groundbreaking companies to advance the prevention, diagnosis, management or care of cancer.

Boston Immune Technologies and Therapies is developing immune-based therapies for cancer to help patients by making treatments more efficacious, cost effective and time efficient. Oncoheroes Biosciences exclusively focuses on the discovery and development of better drugs to help children and adolescents with cancer. Valo Therapeutics is developing novel, patented therapeutic immunotherapy platforms to help cancer patients by uniquely addressing all four objectives key to successful cancer therapy.

Eleven finalists, all of whom represent companies founded by cancer patients, cancer survivors or those with loved ones affected by cancer, were invited to compete at the Lyfebulb-Helsinn Cancer Innovation Summit on January 30, 2020, at the Grimaldi Forum in Monaco during the 14th Monaco Biennale of Oncology. The Summit kicked off with a presentation by Dr. Giulio Draetta, Chief Scientific Officer of MD Anderson, that highlighted the new direction his organization is taking to drive innovation in cancer research.  An independent panel of judges, which included diverse experts in the cancer, healthcare and business communities, listened to the pitches and selected Russell and Cesare as the winners of the two $25,000 monetary grants, and added Michael with a $5,000 grant, to further develop their potential solutions.

“The outstanding diversity and innovations of the 11 finalists attest to the growing reputation of the Challenge that we are running together with Helsinn for a third year in a row.  Additionally, this year, during the Summit, we included an inspirational, moving presentation by a two-time cancer survivor, Kimberly Irvine. We saw firsthand that the combination of patients and care partners working alongside industry is an important key to success,” said Dr. Karin Hehenberger, CEO and Founder of Lyfebulb.

Riccardo Braglia, Helsinn Group Vice Chairman and CEO, said, “The caliber of submissions for this year’s awards was extremely high and we would like to congratulate all those who made it to the Summit. We congratulate Russell, Cesare and Michael and would also like to extend our thanks to the expert panel of judges who had to choose between so many worthy finalists. These awards are testament to the many entrepreneurs out there who are using their own personal experiences to bring innovation and new solutions to the challenges of cancer. Helsinn is proud to support innovation of this quality and looks forward to supporting budding entrepreneurs in coming years.”

About Lyfebulb

Lyfebulb is a chronic disease-focused, patient empowerment platform that connects patients and industry to support user-driven innovation. Grounded with its strong foundation in diabetes, the company has expanded disease states covered into cancer, inflammatory bowel disease, multiple sclerosis, mental health, migraine and transplantation.

See www.lyfebulb.com, Facebook, Twitter, Instagram, Lyfebulb LinkedIn, and Karin Hehenberger LinkedIn.

About the Helsinn Groups

Helsinn is a privately-owned pharmaceutical group with an extensive portfolio of marketed cancer care products and a robust drug development pipeline. Since 1976, Helsinn has been improving the everyday lives of patients, guided by core family values of respect, integrity and quality. The Group works across pharmaceuticals, biotechnology, medical devices and nutritional supplements and has expertise in research, development, manufacture and the commercialization of therapeutic and supportive care products for cancer, pain and inflammation and gastroenterology. In 2016, Helsinn created the Helsinn Investment Fund to support early-stage investment opportunities in areas of unmet patient need. The company is headquartered in Lugano, Switzerland, with operating subsidiaries in Switzerland, Ireland, the U.S., Monaco and China, as well as a product presence in approximately 190 countries globally.

To learn more about Helsinn Group please visit www.helsinn.com

About Helsinn Investment Fund S.A., SICAR

The Helsinn Investment Fund is focused on investments in areas of high unmet patient need. Backed by the Helsinn Group, and guided by Helsinn’s core values of quality, integrity and respect, Helsinn Investment Fund aims to help companies with innovative technologies to transform new ideas into commercial solutions with the potential to impact health-related quality of life of patients.

Drawing on Helsinn’s over 40 years of investment into research and development and commercial expertise, the investment fund selects companies with technologies in a range of areas including cancer therapeutics and diagnostics, cancer supportive care, metabolic and gastrointestinal disorders, and dermatology conditions.

For more information, visit www.helsinninvestmentfund.com

About Helsinn International Services sarl

Helsinn International Services sarl is the Helsinn subsidiary which provides a range of advisory services and strategic activities to the Group and its specific companies. In particular, it acts as the advisory company to Helsinn Investment Fund.

For more information:
Helsinn Group Media Contact
Paola Bonvicini
Group Head of Communication
Lugano, Switzerland
Tel: +41 (0) 91 985 21 21
Info-hhc@helsinn.com
For more information, please visit www.helsinn.com and follow us on Twitter, LinkedIn and Vimeo.

Lyfebulb Media Contact:
Karin Hehenberger, MD, PhD
CEO & Founder, Lyfebulb
Phone: + 1 917-575-0210
Email: karin@lyfebulb.com

NTB natives reject cable car to protect, preserve Mt Rinjani

Mataram, W Nusa Tenggara (ANTARA) – Indigenous people of North Bayan, Lombok Island, West Nusa Tenggara (NTB), expressed their rejection to a plan to develop a cable car facility to protect and preserve Mount Rinjani considered as a source of life.

“Mount Rinjani is a source of life akin to water for the entire Lombok Island,” Raden Akria Buana, Bayan indigenous community leader, concurrently Senaru village chief, told Antara here on Friday.

Mount Rinjani holds spiritual significance for the indigenous people of Bayan residing in the districts of North Lombok and Sembalun, East Lombok.

Preserving Mount Rinjani has become a hereditary tradition for the Bayan people, he pointed out.

Local village heads are responsible for protecting the flora and fauna on Mount Rinjani. The flora and fauna must be protected from modern equipment that could damage them, he remarked.

The natives believe Mount Rinjani is a home of the spirits that guard the mountain. Hence, they routinely hold offering rituals on the mountain, which is popular among local and foreign tourists for hiking.

To this end, the Bayan indigenous people have vehemently rejected the plan to construct a cable car on Mount Rinjani, he remarked.

“We strongly reject the development plan. We do not want Mount Rinjani to be damaged,” he emphasized.

Earlier, Head of NTB’s Environment and Forestry (LHK) Office, Madani Mukarom, confirmed a plan to construct a cable car, with the backdrop of the Mount Rinjani National Park (TNGR) in Lombok.

He remarked that the planned cable car, to be built by PT Indonesia Lombok Resort, will stretch 10 kilometers long and pass Aik Berik Village, North Batukliang Sub-district, Central Lombok District.

The planned cable car’s tracks will be within the protected forest area and the community forest park (Tahura) area and not in the Mount Rinjani area, he

Source: ANTARA News

Indonesia upholds 1945 Constitution over Palestine issue: spokesman

Jakarta (ANTARA) – Indonesia upholds its 1945 Constitution in connection with the Palestinian issue, President Joko Widodo’s spokesman, Fadjroel Rachman, stated in response to US President Donald Trump’s peace plan.

“In accordance with Foreign Minister Retno Marsudi’s directive, once again Indonesia affirms that concerning the Palestinian issue, the Indonesian Government upholds the mandate of the 1945 Constitution consistently,” Rachman noted in a statement here on Thursday.

The 1945 Constitution explicitly states that independence is the right of every nation, so colonialism in the world must be abolished, as it is against humanity and justice, according to the spokesman.

Hence, the solution to the Palestinian problem must be based on the two-state principle that respects international law and parameters agreed upon internationally.

“Indonesia also continues to actively revive dialog that involves concerned parties to achieve stability and lasting peace,” Fadjroel stated.

On January 29, 2020, the Indonesian Foreign Affairs Ministry had issued a press statement saying that Indonesia underscores that to handle the issue of Palestine, Indonesia will consistently uphold the mandate of our Constitution. “The issue of Palestine shall be resolved based on the principles of the ‘two-state solution’ that respects international law and internationally agreed parameters,” the statement noted.

Indonesia once again encourages the resumption of dialog among relevant parties to achieve stability and lasting peace.

In the meantime, US President Donald Trump revealed a peace plan referred to as the “deal of the century” to resolve the Israeli-Palestinian conflict on Tuesday, but Palestinians termed the proposal dead on arrival and Abbas reacted with “a thousand no’s” to the announcement.

Palestinian President Mahmoud Abbas will visit the United Nations within two weeks to address the Security Council on his rejection of Trump’s peace plan, Aljazeera reported.

During that time, a draft resolution will be submitted to the council, Palestinian Ambassador to the UN Riyad Mansour told reporters on Wednesday, without specifying a date for the visit. Trump’s plan, which he announced alongside Israeli Prime Minister Benjamin Netanyahu in Washington, DC, describes Jerusalem as the “undivided capital” of Israel and promises a new capital on the outskirts of eastern Jerusalem for a proposed State of Palestine.

It would also give Israel control over the illegal settlements in the occupied West Bank and the strategic Jordan Valley.

Source: ANTARA News